Market Trends & Sentiment - Bitcoin reached a new all-time high, driving increased interest in Ethereum [1] - Ethereum sentiment is exploding, with ETH treasury firms stockpiling billions and Fidelity framing ETH as a store-of-value [1] - Mainstream media is finally paying attention to Ethereum [1] Key Events & Developments - An ICO will kick off this weekend [2] - Hyperliquid is outperforming Solana [1][2] - Robinhood is pushing tokenized stocks [1] - Prediction markets are facing a credibility crisis [1] - Jack introduced a decentralized messaging system without internet [2] Financial Figures & Investments - An $8.6 billion Bitcoin whale awakening was observed [1] - Pump's ICO is valued at $4 billion [1]

Core Insights - Cerevance is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases and obesity, with presentations scheduled at the Alzheimer's Association International Conference (AAIC) 2025 [1] Group 1: Upcoming Presentations - Cerevance will present a Phase 1 study on CVN293, an investigational inhibitor targeting NLRP3-mediated neuroinflammation, on July 28, 2025 [2] - Another presentation will focus on the NETSseq platform, revealing insights into astrocyte function in Alzheimer's disease, scheduled for July 30, 2025 [2] Group 2: NETSseq Platform - The NETSseq platform allows for the identification of subtle molecular changes driving disease progression by analyzing brain tissue from over 20,000 donors aged 8 to 104 [3] - This platform aids in identifying low-level expressed targets and rare cell types, enhancing the understanding of neurodegenerative diseases [3] Group 3: CVN293 Overview - CVN293 is a selective oral inhibitor of KCNK13, aimed at reducing neuroinflammation and potentially modifying disease progression in neurodegenerative disorders [4] - The mechanism of CVN293 may also provide therapeutic benefits for obesity, identified through the NETSseq platform [4] Group 4: Company Pipeline - Cerevance's lead investigational treatment, solengepras, is in Phase 3 development for Parkinson's disease, while CVN766 targets binge eating disorder and schizophrenia [5] - CVN293 represents a novel intervention point for both neurodegenerative disorders and obesity [5]

Market Trends & Dynamics - Bitcoin is hitting new records while the dollar is moving higher, a deviation from the typical inverse relationship [1] - The current Bitcoin rally appears to have more staying power compared to the blip in May 2022 [2] - A tech stock rally pushed Bitcoin to a ceiling around $110,000, triggering significant short liquidations [3] Cryptocurrency Performance - Over $600 million in Bitcoin short liquidations and over $200 million in Ether short liquidations occurred in the past 24 hours [3] - The biggest buying day of the year in both Bitcoin and Ethereum ETFs was observed [4] - Ethereum has been outperforming Bitcoin in recent months, experiencing a resurgence [6] Ethereum's Use Cases & Potential - Ethereum's rally is potentially a reflection of its practical use cases, as it allows for building applications on top of it [5] - Major brands like Amazon, Walmart, Uber, and Airbnb are showing interest in the stablecoin game, with Ethereum serving as the backbone for stablecoins and tokenization of stocks [8]

RT Token Terminal 📊 (@tokenterminal)🚨 BREAKING: Quarterly stablecoin transfer volume on @ethereum surpassed $4 trillion in Q2 '25.An all-time high. https://t.co/zn182USPfN ...

ETH reclaims $3,000 as BlackRock's spot Ethereum ETF notches $300 million in record daily inflows https://t.co/8nM8dMswHl ...

🚨REMINDER:$5,101,900,000 WORTH OF BITCOIN AND ETHEREUM OPTIONS WILL EXPIRE TODAY. ...

Core Viewpoint - Concerns are rising over the potential impact of new tariffs on Europe, leading to increased costs for credit default swaps (CDS) as investors seek to hedge against credit default risks in the Eurozone [1] Group 1: Market Reactions - The iTraxx Europe Crossover index, which tracks junk-rated corporate bonds in the Eurozone, has increased by 5 basis points to 283 basis points [1] - The announcement of tariffs by the U.S. has reignited fears among investors regarding the progress of trade negotiations between the U.S. and the EU [1] Group 2: Analyst Insights - Patrick Munelli, an analyst at Tickmill Group, highlighted that the U.S. has sent a tariff letter to the EU, indicating that trade talks are not progressing smoothly [1]

Weed Rx: “Pharmaceutical cannabis is the biggest future for cannabis,” says Joel Stanley (left, with his brother Jared), founder of Ajna BioSciences, which has a botanical drug in the FDA pipeline. https://t.co/Q2rTHfUQwO https://t.co/Q2rTHfUQwO ...

Where Is Cannabis Legal In Europe? https://t.co/hnhQuy6l8s https://t.co/hnhQuy6l8s ...

When you hear “RWAs”, you should think Ethereum. https://t.co/qozF4BCemC ...